MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
Glioblastomas are the most malignant gliomas with median survival times of only 15 months despite modern therapies. All standard treatments are palliative. Pathogenetic factors are diverse, hence, stratified treatment plans are warranted considering the molecular heterogeneity among these tumors. Ho...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2007-01-01
|
| Series: | Disease Markers |
| Online Access: | http://dx.doi.org/10.1155/2007/159242 |